Merck
Just take a look at the drugs on pace to become blockbusters this year:
Drug |
Current Seller |
Sales (in millions) |
Year-Over-Year Increase (decrease) |
---|---|---|---|
Singulair |
Merck |
$1,300 |
16% |
Zetia and Vytorin |
Merck and Schering |
$1,000 |
(10%) |
Cozaar and Hyzaar |
Merck |
$906 |
(4%) |
Remicade |
Schering |
$565 |
2% |
Januvia |
Merck |
$462 |
38% |
Nasonex |
Schering |
$321 |
3% |
Gardasil |
Merck |
$268* |
(18%) |
Temodar |
Schering |
$256 |
2% |
*Excludes sales from joint venture with sanofi-aventis
With the exception of Januvia, nothing stands out as stellar. The increase in sales of Singulair is impressive, especially since growth was stunted last year as doctors worried about reports of increased suicide risk, but the U.S. patent expires in 2012, so there isn't too much more room to run.
Sales growth of Remicade would have been 19% if the stronger dollar hadn't smacked the year-over-year comparison down, but Merck and Schering aren't guaranteed to be able to sell the drug once they wed. Partner Johnson & Johnson
In total, Merck's sales were up 3%, excluding the negative impact of currency exchanges; the smaller Schering saw sales increase 4%, excluding currency changes. That's nothing to write home about, even if it was better than expected.
I liked the Merck and Schering deal more than the Pfizer
We're married to Foolishness:
- 5 stocks under $10.
- The next 3 dividend dynamos.
- Best buys now.